Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VGX Pharmaceuticals has submitted an investigational new drug application to the FDA for Phase I clinical studies of VGX-3200 in late stage cancer patients.
Subscribe to our email newsletter
The proposed human studies with plasmid-delivered Growth Hormone Releasing Hormone (GHRH) follow successful studies in dogs with cancer. Administration of GHRH plasmid with VGX’s Cellectra electroporation device was shown to increase IGF-I levels, ameliorate cachexia, improve anemia, prolong survival, and improve quality of life in dogs with cancer.
VGX-3200 is an injectable DNA plasmid-based therapeutic that expresses GHRH protein. Treatment for cancer-related cachexia and anemia is the first target for VGX-3200. Additionally, the company is developing the GHRH technology for a number of other indications including age-related disorders.
Joseph Kim, president and CEO of VGX, said: “We plan to file two additional INDs for our SynCon product candidates during the first two quarters of 2008: VGX-3100, a therapeutic vaccine for the treatment of cervical cancer and VGX-3400, a pandemic avian flu vaccine.”